Chemistry:JXL069
JXL069 is an experimental drug originally developed at the University of California, Los Angeles (UCLA) and licensed for development to Pelage Pharmaceuticals, which acts as a potent and selective mitochondrial pyruvate carrier (MPC) inhibitor that disrupts pyruvate import into mitochondria. It has been researched as a potential treatment for androgenetic alopecia and shows positive results in animal studies. Pelage Pharmaceuticals currently has a related candidate molecule PP405 in phase 2 clinical trials for hair loss formulated as a topical cream for the scalp.[1][2] MPC inhibitors also have potential for the treatment of cancer, so a large number of related molecules have also been developed, of which JXL069 was among the most effective tested so far for treatment of hair loss.[3][4][5][6][7][8] The drug is known to have been sold online in a grey market fashion for treatment of hair loss.[9] It has been believed to be PP405, but PP405 was said not to be JXL069 by Pelage Pharmaceuticals.[9]
See also
References
- ↑ "Regenerative Medicine in Action: Topical PP405 Shows Promise in Androgenetic Alopecia.". The Dermatology Digest. 17 June 2025. https://thedermdigest.com/regenerative-medicine-in-action-topical-pp405-shows-promise-in-androgenetic-alopecia/.
- ↑ "Pelage's PP405 Demonstrates Efficacy in Phase 2a Trial for Androgenetic Alopecia.". Dermatology Times. 23 June 2025. https://www.dermatologytimes.com/view/pelage-s-pp405-demonstrates-efficacy-in-phase-2a-trial-for-androgenetic-alopecia.
- ↑ Lowry WE, et al., "Compositions and methods for modulating hair growth.", WO patent 2019/006359, published 3 January 2019
- ↑ Sun DL, et al., "Compounds for treatment of hair loss.", WO patent 2023/129854, published 6 July 2023
- ↑ "Development of Novel Mitochondrial Pyruvate Carrier Inhibitors to Treat Hair Loss". Journal of Medicinal Chemistry 64 (4): 2046–2063. February 2021. doi:10.1021/acs.jmedchem.0c01570. PMID 33534563.
- ↑ "Identification of Novel Mitochondrial Pyruvate Carrier Inhibitors by Homology Modeling and Pharmacophore-Based Virtual Screening". Biomedicines 10 (2): 365. February 2022. doi:10.3390/biomedicines10020365. PMID 35203575.
- ↑ "Design, synthesis and biological evaluation of novel cyano-cinnamate derivatives as mitochondrial pyruvate carrier inhibitors". Bioorganic & Medicinal Chemistry Letters 112. November 2024. doi:10.1016/j.bmcl.2024.129923. PMID 39134097.
- ↑ "Advances in the Development of Mitochondrial Pyruvate Carrier Inhibitors for Therapeutic Applications". Biomolecules 15 (2): 223. February 2025. doi:10.3390/biom15020223. PMID 40001526.
- ↑ 9.0 9.1 Brown, Lane (12 August 2025). "The Great Unbalding Draws Nearer". https://nymag.com/intelligencer/article/pp405-baldness-cure-hair-loss-treatment-follicles-science-tressless.html.
 |  |
